Poorer educational outcomes may need to be added to the list of the potential outcomes for children who have type 1 diabetes.
Poorer educational outcomes may need to be added to the list of the potential outcomes for children who have type 1 diabetes. A new study published in Diabetes Care examines the connection.
Researchers used 9 databases from across Scotland that included hospital admissions, maternity records, dispensed prescriptions, diabetes registered, death certificates, school absences/exclusions, school examination, annual pupil census, and unemployment, which resulted in a cohort of 766,047 single-birth children who were born and attended school in Scotland between 2009 and 2013. Within that cohort, 3330 children were treated for type 1 diabetes.
The children treated for type 1 diabetes were more likely than their peers who did not have the condition to be absent from school, have some form of learning difficulty, be admitted to a hospital, and die. In the cohort of children with type 1 diabetes, the children with a higher HbA1c measurement, particularly those with a measurement in the highest quintile, were more likely to have an increased risk of exclusion, a greater rate of absenteeism, poorer attainment of education, and a higher risk of being unemployed.
The researchers highlighted the need to develop interventions to reduce school absenteeism and to ensure that children with type 1 diabetes are able to attain needed education.
Crinecerfont safe, effective in treating children with congenital adrenal hyperplasia
October 10th 2023Crinecerfont, an investigational, oral, selective corticotropin-releasing factory type 1 receptor antagonist, achieved the primary and key secondary endpoints in a phase 3 study to treat congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children aged 2 to 17 years.
FDA approves teplizumab for delay of type 1 diabetes in patients 8 years and up
November 18th 2022The US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.